Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Wegovy, other weight-loss drugs might help with alcoholism, opioid addiction
Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.
Why Ozempic, Zepbound, and other weight-loss drug dupes carry risks
Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.
Next-gen weight loss drugs will have fewer side effects than Ozempic, pharma CEO says
Zealand Pharma CEO Adam Steensberg said Friday that the company is working on a next-generation weight loss drug that’s designed to work differently from those currently on the market and with the potential for fewer side effects.
Off-brand Ozempic, Zepbound and other weight loss products carry undisclosed risks for consumers
Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ingredients that may lack the purity of the branded medications.
ConsumerAffairs
19h
Compounding pharmacies can keep making Mounjaro and Zepbound copies
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
6h
on MSN
This is Huge News For Eli Lilly Investors
Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.
2d
on MSN
Eli Lilly’s Zepbound to undergo first-of-its-kind study on economic impact
Eli Lilly (NYSE:LLY) has partnered with the British government to launch a first-of-its-kind real-world study to evaluate the ...
2d
on MSN
FDA shakes up weight loss market as Mounjaro shortage ends
Federal regulators shook up the booming weight loss drug marketplace when they announced Mounjaro and Zepbound to be no ...
6d
on MSN
Wegovy and Zepbound rival targeting ‘next generation' of obesity drugs, Zealand Pharma CEO says
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
2h
2 High-Flying Growth Stocks With Massive Upside Potential
The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...
3d
FDA, facing pressure, to review position on Zepbound, Mounjaro shortage
The agency agreed in court to allow compounding companies to continue producing copycat versions of Lilly’s fast-selling ...
USA Today
13d
Mounjaro, Zepbound shortage eases as supplies of weight loss drug rebound
Eli Lilly's tirzepatide, sold as
Zepbound
for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...
13d
Ozempic for all, Zepbound is back, and the top CEO pay: Pharma news roundup
The mayor of Rio de Janeiro is promising to make a generic version of Ozempic available through the city’s public health ...
6d
Eli Lilly Expects Zepbound Approval in Japan by Mid-2025, Eyes Weight-Loss Market
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
1d
on MSN
Eli Lilly vs. Novo Nordisk: Which Weight Loss Stock is The Better Opportunity Over The Next 10 Years?
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Eli Lilly and Company
Mounjaro
tirzepatide
Wegovy
Feedback